Dimerix Limited Stock

DXB

AU000000DXB7

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 10:10:17 24/07/2026 +04			5-day change	1st Jan Change
0.2500 ^AUD	+4.17%		+4.17%	-54.55%

07-23	Dimerix Secures US Patent Regarding Kidney Injury Drug Candidate, Shares Jump 4%	MT
07-17	Dimerix Limited and Mission Therapeutics Limited Expand Pipeline with Acquisition of Phase 2 Ready Asset for Acute Kidney Injury	CI

Analysts' recommendations: Dimerix Limited

07-17	Dimerix Hits 'Major Milestone' With AU$10 Million Financing Package, Euroz Hartleys Says	MT
06-17	Dimerix's Everest Deal Adds Value, Eases Funding Concerns, Euroz Hartleys Says	MT
05-01	Dimerix's Potential Non-Dilutive Funding May Lead to Ongoing Phase Three Trial Being Fully Funded, Euroz Hartleys Says	MT
04-14	Dimerix Poised to Benefit From US FDA's Approval of Travere Therapeutics' Kidney Disorder Drug, Euroz Hartleys Says	MT
04-08	Dimerix Sees No Impact From US Pharma Tariffs, Says Euroz Hartleys	MT

More recommendations

Press Releases: Dimerix Limited

07-17	Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline	AQ
06-17	Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia	AQ
01/05/25	Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States	AQ
05/10/23	ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand	AQ
27/07/22	Dimerix : Quarterly Appendix 4C and Activities Report	PU

More press releases

Managers and Directors: Dimerix Limited

Manager	Title	Age	Since
Nina Webster CEO	Chief Executive Officer	-	27/08/2018
Michael Tonroe DFI	Director of Finance/CFO	59	29/01/2026
David Fuller CTO	Chief Tech/Sci/R&D Officer	-	01/10/2023

Director	Title	Age	Since
Sonia Maria Poli BRD	Director/Board Member	61	03/07/2015
Hugh Alsop CHM	Chairman	-	-
Nina Webster BRD	Director/Board Member	-	27/08/2018

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIMERIX LIMITED	+4.17%	+4.17%	-54.55%	+233.33%	100M
LONZA GROUP AG	+1.57%	-3.17%	-2.93%	+13.24%	46.35B
REVOLUTION MEDICINES, INC.	+3.13%	+5.34%	+402.93%	+605.08%	40.13B
BEONE MEDICINES AG	+2.14%	+2.95%	+10.83%	+65.45%	36.33B
IQVIA HOLDINGS INC.	+4.43%	-1.51%	+6.73%	-9.17%	34.6B
CELLTRION, INC.	+1.23%	-2.05%	+0.56%	+30.76%	26.77B
ASCENDIS PHARMA A/S	+0.29%	-2.75%	-	-	16.66B
MEDPACE HOLDINGS, INC.	+14.71%	+12.62%	+38.50%	+146.99%	16.91B
EUROFINS SCIENTIFIC SE	+0.67%	-5.29%	+1.00%	+8.76%	13.05B
ICON PUBLIC LIMITED COMPANY	+1.82%	+0.19%	+1.45%	-30.74%	13.05B
Average	+3.42%	+0.42%	+44.95%	+118.19%	24.39B
Weighted average by Cap.	+3.07%	+0.23%	+76.35%	+131.99%

See all sector performances

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/07/26	A$0.2500	+4.17%	1,091,226
23/07/26	A$0.2400	-4.00%	2,448,999
22/07/26	A$0.2500	+8.70%	1,986,809
21/07/26	A$0.2300	+2.22%	688,279
20/07/26	A$0.2250	-6.25%	2,190,009

Delayed Quote Australian S.E.

More quotes

Income Statement and Estimates

More financial data

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	123M 85.8M 75.46M 70.1M 64.48M 121M 8.31B 838M 327M 4.05B 322M 315M 14.06B	P/E 2024	-13.5x	P/E 2025	-24.3x
Enterprise Value	54.9M 38.27M 33.66M 31.27M 28.76M 53.93M 3.71B 374M 146M 1.81B 144M 141M 6.27B	EV / Sales 2024	443x	EV / Sales 2025	49.4x
Free-Float	77.77%	Yield 2024 *	-	Yield 2025	-

1 day	+4.17%
1 week	+4.17%
Current month	+21.95%
1 month	+28.21%
3 months	-34.21%
6 months	-52.38%
Current year	-54.55%

1 week	0.22	0.26
1 month	0.19	0.27
Current year	0.16	0.56
1 year	0.16	0.66
3 years	0.06	0.78
5 years	0.05	0.78
10 years	0.05	0.78

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/12/25	Hugh Alsop	Free	Director	100,000	0.0167%
12/12/25	Clinton Snow	Free	Director	100,000	0.0167%
12/12/25	Mark Diamond	Free	Chairman	100,000	0.0167%

	2024	2025
Net sales	583K 407K 358K 332K 306K 573K 39.39M 3.97M 1.55M 19.21M 1.53M 1.49M 66.65M	5.59M 3.89M 3.43M 3.18M 2.93M 5.49M 377M 38.05M 14.84M 184M 14.62M 14.3M 638M
Net income	-17.08M -11.9M -10.47M -9.73M -8.94M -16.77M -1.15B -116M -45.36M -562M -44.69M -43.72M -1.95B	-13.25M -9.24M -8.12M -7.55M -6.94M -13.02M -895M -90.26M -35.2M -436M -34.68M -33.93M -1.51B
Net Debt	-21.99M -15.33M -13.48M -12.53M -11.52M -21.6M -1.48B -150M -58.42M -724M -57.55M -56.31M -2.51B	-68.19M -47.53M -41.81M -38.84M -35.72M -66.99M -4.6B -464M -181M -2.25B -178M -175M -7.79B

Dimerix Limited Stock

Stocks

DXB

AU000000DXB7

Biotechnology & Medical Research

Valuation: Dimerix Limited

Chart: Dimerix Limited

Latest news : Dimerix Limited

Analysts' recommendations: Dimerix Limited

Press Releases: Dimerix Limited

Quotes and Performance

Course Extremes

Managers and Directors: Dimerix Limited

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates